Bausch + Lomb Corp
BLCO17.000USD
+0.615+3.75%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
6.02BMarket Cap
LossP/E TTM
More Details of Bausch + Lomb Corp Company
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Bausch + Lomb Corp Info
Ticker SymbolBLCO
Company nameBausch + Lomb Corp
IPO dateMay 06, 2022
CEOSaunders (Brenton L)
Number of employees13500
Security typeOrdinary Share
Fiscal year-endMay 06
Address520 Applewood Crescent
CityVAUGHAN
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryCanada
Postal codeL4K 4B4
Phone19082552864
Websitehttps://ir.bausch.com/
Ticker SymbolBLCO
IPO dateMay 06, 2022
CEOSaunders (Brenton L)
Company Executives of Bausch + Lomb Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+6146.00%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+17715.00%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+1642.00%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
52.37K
+35034.00%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+6146.00%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+17715.00%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
66.56K
+1642.00%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
52.37K
+35034.00%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Devices
484.00M
37.78%
OTC
454.00M
35.44%
Pharmaceuticals
280.00M
21.86%
Branded and other Generics
59.00M
4.61%
Other revenues
4.00M
0.31%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Devices
484.00M
37.78%
OTC
454.00M
35.44%
Pharmaceuticals
280.00M
21.86%
Branded and other Generics
59.00M
4.61%
Other revenues
4.00M
0.31%
Shareholding Stats
Updated: Sat, Nov 22
Updated: Sat, Nov 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bausch Health Companies Inc
87.62%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
Other
8.56%
Shareholders
Shareholders
Proportion
Bausch Health Companies Inc
87.62%
Icahn Enterprises LP
0.99%
Deutsche Bank Securities Inc.
0.99%
Alberta Investment Management Corporation
0.92%
Oaktree Capital Management, L.P.
0.92%
Other
8.56%
Shareholder Types
Shareholders
Proportion
Corporation
87.62%
Hedge Fund
3.73%
Investment Advisor/Hedge Fund
3.02%
Research Firm
1.67%
Investment Advisor
1.62%
Holding Company
0.99%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Family Office
0.24%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
247
42.63M
17.16%
+11.66K
2025Q3
260
42.62M
19.43%
+3.57M
2025Q2
253
39.09M
18.05%
+715.03K
2025Q1
249
38.33M
16.53%
-19.93M
2024Q4
239
35.61M
16.96%
-2.09M
2024Q3
234
37.72M
16.36%
-3.49M
2024Q2
237
40.61M
17.42%
+3.09M
2024Q1
226
37.49M
18.08%
-25.96M
2023Q4
216
38.90M
17.69%
-4.13M
2023Q3
198
43.02M
17.49%
-1.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bausch Health Companies Inc
310.45M
87.65%
--
--
Mar 24, 2025
Icahn Enterprises LP
3.50M
0.99%
--
--
Sep 30, 2025
Deutsche Bank Securities Inc.
3.50M
0.99%
+89.90K
+2.64%
Sep 30, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
Oaktree Capital Management, L.P.
3.25M
0.92%
+724.19K
+28.72%
Sep 30, 2025
GoldenTree Asset Management, LP
2.66M
0.75%
+77.32K
+2.99%
Sep 30, 2025
D. E. Shaw & Co., L.P.
2.61M
0.74%
--
--
Sep 30, 2025
Silver Point Capital, L.P.
2.56M
0.72%
+2.56M
--
Sep 30, 2025
Fidelity Management & Research Company LLC
1.56M
0.44%
+788.29K
+102.13%
Sep 30, 2025
Glenview Capital Management, LLC
1.55M
0.44%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Ballast Small/Mid Cap ETF
1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Schwab Fundamental International Small Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
AltShares Event-Driven ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
BNY Mellon US Mid Cap Core Equity ETF
0%
View more
Ballast Small/Mid Cap ETF
Proportion1.4%
Invesco RAFI Developed Mkts ex-US SM ETF
Proportion0.03%
BNY Mellon US Small Cap Core Equity ETF
Proportion0.03%
Schwab Fundamental International Small Equity ETF
Proportion0%
Goldman Sachs MarketBeta US 1000 Equity ETF
Proportion0%
Invesco Zacks Mid-Cap ETF
Proportion0%
QRAFT AI-Enhanced US Large Cap ETF
Proportion0%
AltShares Event-Driven ETF
Proportion0%
DFA Dimensional International Core Equity 2 ETF
Proportion0%
BNY Mellon US Mid Cap Core Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
